Immunophotonics, Inc. is a clinical-stage biotech with a novel approach to address the challenge of significantly delaying or preventing cancer recurrence and metastasis. The proprietary phase 2 asset, IP-001, used in conjunction with routine tumor destruction interventions such as tumor ablation or radiation is designed to ignite an anti-tumor immune response. This entirely in situ approach has demonstrated excellent safety and tumor-shrinking efficacy across solid tumor indications in over 100 patients.